News Sentiment

PVLA sentiment intelligence

Palvella Therapeutics, Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 157.24 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+8.6% over one week, +39.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 8.6% Price confirming higher
Trend fit Trend active 39.0% over four weeks
Fair value 131.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 37
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 10
Quiver Quantitative 5
Investing.com 4
simplywall.st 4
Stock Titan 3
Moomoo 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 15
Analyst action 4
Deals and strategy 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

[Form 4] PALVELLA THERAPEUTICS, INC. Insider Trading Activity

Palvella Therapeutics, Inc.'s Chief Operating Officer, Kathleen Goin, reported exercising and selling 4,302 shares of common stock on July 15, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred across four transactions at weighted average prices ranging fro

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 19:40
Source
Stock Titan
Market source Direct company coverage

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN

Palvella Therapeutics (PVLA) has submitted the initial module of its New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin anhydrous gel, a treatment for microcystic lymphatic malformations. The company plans to complete the NDA application in the latter half of 2026 an

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 13:01
Source
Market source
TradingView Direct company coverage

Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash

Palvella Therapeutics recently released a corporate presentation detailing positive Phase 3 SELVA results and plans for a potential U.S. launch of QTORIN™ rapamycin for microcystic LMs in the first half of 2027. The company has a strong financial position with $262 million cash a

Tone
Positive 70/100
Event
Earnings
Published
15 Jul 2026 10:10
Source
TradingView
Quartr Direct company coverage

Palvella Therapeutics (PVLA) Proxy filing Summary

Palvella Therapeutics (PVLA) has released a summary of its proxy filing for its annual meeting scheduled for June 10, 2026. Key voting matters include the election of three Class III director nominees, the ratification of Ernst & Young as the independent public accounting firm, a

Tone
Positive 69/100
Event
Market update
Published
11 Jul 2026 07:40
Source
Quartr
TradingView Direct company coverage

Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA

This article provides financial information for Palvella Therapeutics, Inc. (NASDAQ: PVLA), specifically focusing on its price-to-book forward metric. It mentions that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to b

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 18:40
Source
TradingView
Market source Direct company coverage

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors

Palvella Therapeutics has announced the appointment of Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls brings over 25 years of experience in the biopharmaceutical industry, particularly in advancing and commercializing therapies for rare diseases. This appointment come

Tone
Positive 75/100
Event
Market update
Published
04 Jul 2026 08:39
Source
Market source
Finviz Direct company coverage

PVLA - Palvella Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview for Palvella Therapeutics Inc (PVLA), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers performance metrics such as volatility, short interest, analyst recommendat

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 11:10
Source
Finviz
The Globe and Mail Direct company coverage

Palvella Therapeutics Adds Industry Veteran to Board

Palvella Therapeutics has expanded its Board of Directors by appointing Matthew Pauls, an industry veteran with extensive experience in biopharmaceuticals and rare diseases, as a Class I director. Pauls brings expertise in commercialization, clinical development, and M&A, which i

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 08:11
Source
The Globe and Mail
Investing.com Direct company coverage

Palvella Therapeutics appoints Matt Pauls to board of directors

Palvella Therapeutics has announced the appointment of Matt Pauls to its board of directors, leveraging his 25 years of biopharmaceutical industry experience. Pauls previously held leadership roles at Savara Inc., Strongbridge Biopharma plc, and Insmed Incorporated, and served on

Tone
Positive 76/100
Event
Market update
Published
30 Jun 2026 12:09
Source
Investing.com
Investing.com Nigeria Direct company coverage

Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com

Palvella Therapeutics has appointed Matt Pauls to its board of directors, leveraging his 25 years of biopharmaceutical industry experience. Pauls, currently chair and CEO of Savara Inc., previously led Strongbridge Biopharma through its Nasdaq IPO and commercialized key therapies

Tone
Positive 72/100
Event
Market update
Published
30 Jun 2026 11:40
Source
Investing.com Nigeria
Investing.com Direct company coverage

Palvella Therapeutics stock hits 52-week high at 151.36 USD

Palvella Therapeutics Inc. (PVLA) has reached a new 52-week high of $151.36, reflecting a 569.92% increase over the past year. Despite its $2.17 billion market capitalization, InvestingPro suggests the stock may be overvalued, although it shows strong momentum. The company recent

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 20:39
Source
Investing.com
grafa.com Direct company coverage

Palvella submits FDA NDA for QTORIN gel

Palvella Therapeutics (NASDAQ:PVLA) has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin gel. This treatment is for microcystic lymphatic malformations, a rare condition affecting over 30,000 patients in the U.S. The compan

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 17:26
Source
grafa.com
Market source Direct company coverage

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations (microcystic LMs). The company expects to complete the NDA submission in the second half of 2026

Tone
Positive 72/100
Event
Guidance
Published
29 Jun 2026 11:12
Source
Market source
Finviz Direct company coverage

PVLA - Palvella Therapeutics Inc Short Interest

This article provides comprehensive financial data for Palvella Therapeutics Inc (PVLA), including its short interest, market capitalization, earnings, sales figures, and various financial ratios. It also details insider and institutional ownership, performance metrics across dif

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:40
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA

This article provides limited information on the "Price to earnings forward" metric for Palvella Therapeutics, Inc. (NASDAQ: PVLA), indicating a period value, change, and percentage change. The content, which appears to be from TradingView, does not include actual financial figur

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:40
Source
TradingView
TradingView Direct company coverage

Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA)

This article provides an overview of Palvella Therapeutics, Inc. (PVLA) stock performance, financial actuals, and analyst estimates. Key information includes the current stock price, historical highs and lows, market capitalization, upcoming earnings reports, and revenue and net

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 12:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA

The article discusses the enterprise value to EBIT forward for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a stub or a section from a larger financial analysis platform, providing a title and indicating that the content would detail this financial metric. The pla

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Palvella Therapeutics, Inc. Actuals & Estimates (LS:A40RA6)

This article provides financial actuals and estimates for Palvella Therapeutics, Inc. (LS:A40RA6), including analyst opinions, historical price data, volatility, market capitalization, and upcoming earnings dates. It highlights that analysts estimate A40RA6's price to range from

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:39
Source
TradingView
Moomoo Direct company coverage

Palvella Therapeutics Insiders Placed Bullish Bets Worth US$850.0k

The article reports that insiders at Palvella Therapeutics recently made bullish investments, purchasing shares valued at US$850,000. These significant insider buys often signal confidence in the company's future prospects and are closely watched by investors as a potential indic

Tone
Positive 77/100
Event
Market update
Published
25 Jun 2026 14:40
Source
Moomoo
TradingView Direct company coverage

Price to earnings forward of Palvella Therapeutics, Inc. – LS:A40RA6

This article provides financial information for Palvella Therapeutics, Inc. (A40RA6) on TradingView. It shows that the market is closed with no trades and displays the "Price to earnings forward" value and period. The content is primarily a data page rather than a descriptive art

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA

This article provides the "Price to sales forward" metric for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a financial data snippet from TradingView, offering a specific valuation ratio for the company without additional commentary or analysis. The content primari

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 15:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Palvella Therapeutics, Inc. – LS:A40RA6

This article provides financial information for Palvella Therapeutics, Inc. (A40RA6) on TradingView, specifically focusing on its forward price-to-book value. It details the company's financial overview, news, and community discussions, all hosted on the TradingView platform whic

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 14:09
Source
TradingView
Investing.com South Africa Direct company coverage

Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com

Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares worth $476,372 on June 17, 2026. This sale followed the acquisition of shares through stock option exercises valued at $34,883 and was executed under a Rule 10b5-1 trading plan. Despite the sale, the sto

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Jun 2026 02:40
Source
Investing.com South Africa